Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
- Author(s)
- Luz, MA; Briganti, A; Murphy, DG; Pieczonka, CM; Suzuki, H; Yu, EY; Artignan, X; Gotto, GT; Hamilton, JP; Malone, RJ; Adorjan, P; Ghadessi, M; Verholen, F; Armstrong, AJ;
- Details
- Publication Year 2026-08-03,Volume 9,Issue #8,Page e2629936
- Journal Title
- JAMA Network Open
- Publication Type
- Research article
- Abstract
- This nonrandomized clinical trial assesses the safety and efficacy of darolutamide, with or without concomitant lipid-modifying agents (LMAs), in treating nonmetastatic castration-resistant prostate cancer.; eng
- Publisher
- JAMA Network
- Department(s)
- Surgical Oncology
- Publisher's Version
- https://doi.org/10.1001/jamanetworkopen.2026.29936
- Open Access at Publisher's Site
https://doi.org/10.1001/jamanetworkopen.2026.29936- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-09-14 12:01:07
Last Modified: 2026-09-14 12:01:21